The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Current Status of Cardiovascular Gene Therapy
Open accessAbstract
Gene transfer for the therapeutic modulation of cardiovascular diseases is an expanding area of gene therapy. During the last decade several approaches have been designed for the treatment of hyperlipidemias, post-angioplasty restenosis, hypertension, and heart failure, and for protection of vascular by-pass grafts and promotion of therapeutic angiogenesis. Adenoviruses (Ads) and adeno-associated viruses (AAVs) are currently the most efficient vectors for delivering therapeutic genes into the cardiovascular system. Gene transfer using local gene delivery techniques have been shown to be superior to less-targeted intra-arterial or intra-venous applications. To date, no gene therapy drugs have been approved for clinical use in cardiovascular applications. In preclinical studies of therapeutic angiogenesis, various growth factors such as vascular endothelial growth factors (VEGFs) and fibroblast growth factors (FGFs), have shown positive results. Gene therapy also appears to have potential clinical applications in improving the patency of vascular grafts and in treating heart failure. Post-angioplasty restenosis, hypertension, and hyperlipidemias (excluding homozygotic familial hypercholesterolemia) can usually be managed satisfactorily by conventional approaches, and are therefore less favored areas for gene therapy. The development of technologies that can ensure long-term, targeted, and regulated gene transfer, and a careful selection of target patient populations, will be very important for the progress of cardiovascular gene therapy in clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice
Lindahl, P., Johansson, B. R., Levéen, P., & Betsholtz, C. (1997) · Science · doi:10.1126/science.277.5323.242 · Cited by 2,226
Cao, R., Bråkenhielm, E., Pawliuk, R., Wariaro, D., Post, M. J., Wahlberg, E., Leboulch, P., & Cao, Y. (2003) · Nature Medicine · doi:10.1038/nm848 · Cited by 721
Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676
Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262
Cited by
Baddour, L. M., Epstein, A. E., Erickson, C. C., Knight, B. P., Levison, M. E., Lockhart, P. B., Masoudi, F. A., Okum, E. J., Wilson, W. R., Beerman, L. B., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192665 · Cited by 1,030
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622
Methods in cardiomyocyte isolation, culture, and gene transfer
Louch, W. E., Sheehan, K. A., & Wolska, B. M. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.06.012 · Cited by 497
Therapeutic angiogenesis for critical limb ischaemia
Annex, B. H. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.70 · Cited by 298
VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond
Giacca, M., & Zacchigna, S. (2012) · Gene Therapy · doi:10.1038/gt.2012.17 · Cited by 252
Metadata
- Authors
- Rissanen, T. T., & Ylä-Herttuala, S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 15
- Issue
- 7
- Pages
- 1233-1247
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2055821904
- Cited by
- 175
- References
- 4
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Status of Cardiovascular Gene Therapy. https://app.cochat.ai/papers/10.1038/sj.mt.6300175
- The paper
- Rissanen, T. T., & Ylä-Herttuala, S. (2007). Current Status of Cardiovascular Gene Therapy. Molecular Therapy. https://doi.org/10.1038/sj.mt.6300175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.